Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm trial of foscenvivint in HIV/HCV-related liver cirrhosis with hemophilia
jRCT2031230461Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of foscenvivint in Cirrhosis, human immunodeficiency virus infection (HIV), hepatitis C virus infection and 1 more, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Change from baseline in ALBI score at 24 weeks after administration. Started May 2024; status: completed.
02
Drugs
foscenvivint
03
Conditions
Cirrhosishuman immunodeficiency virus infection (HIV)hepatitis C virus infectionhemophilia
Beyond the preview
Go deeper on jRCT2031230461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230461.